Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric maribavir study in CMV infection after HSCT or SOT
2021-004279-15Phase 3Active
- Sponsor
- Takeda
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maribavir in cytomegalovirus disease (CMV), sponsored by Takeda. Primary endpoint: Pharmacokinetic parameters at steady state at Week 1. Started Apr 2022; status: active.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2021-004279-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004279-15.